IP Library Granted Patent US 7,763,269
Granted Patent B2
US 7,763,269 · App. 10/522,528 · Granted Jul 27, 2010

Therapeutic foam

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,763,269
App. No.
10/522,528
Granted
Jul 27, 2010
Kind
B2
Abstract

A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.

Claims (24)

1. A method of making a foam comprising:

providing two syringes connected by a connector, wherein syringe one is charged with a liquid phase and syringe two is charged with a gas phase, syringe one is charged with the liquid phase and the gas phase, or both syringes are charged with the liquid phase and the gas phase; and

transferring the liquid phase and the gas phase repeatedly between the syringes to form a foam, wherein

the liquid phase comprises at least one sclerosing agent and

the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen.

2. The method of claim 1 , wherein the liquid phase and gas phase passing between the syringes is caused to pass through a mesh comprising apertures with a maximum dimension ranging from 1 to 200 micron.

3. The method of claim 2 , wherein the maximum dimension ranges from 2 to 50 micron.

4. The method of claim 2 , wherein the maximum dimension ranges from 3 to 20 micron.

5. The method of claim 1 , wherein the gas phase is at least 70% by volume oxygen.

6. A method of making a foam comprising:

(a) providing a syringe comprising a barrel, a first plunger and a second plunger, the second plunger having an apertured plunger head which is adapted to be movable within the barrel independently of the first plunger, the syringe being charged with a liquid phase and a gas phase; and

(b) oscillating the second plunger to form a foam;

wherein

the liquid phase comprises at least one sclerosing agent and

the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen.

7. The method of claim 6 , wherein the apertures in the second plunger have a maximum dimension ranging from 1 to 200 micron.

8. The method of claim 6 , wherein the apertures in the second plunger have a maximum dimension ranging from 2 to 50 micron.

9. The method of claim 6 , wherein the apertures in the second plunger have a maximum dimension ranging from 3 to 20 micron.

10. The method of claim 6 , wherein the gas phase is at least 70% by volume oxygen.

11. A sterile pack comprising:

(a) a syringe charged with at least one liquid sclerosing agent and a gas mixture consisting essentially of gaseous nitrogen present in an amount ranging from 0.01% to 0.8% by volume and a physiologically acceptable gas mixture comprising 10% to 90% vol/vol carbon dioxide with the remaining gas oxygen;

(b) a gas atmosphere inside the pack having substantially the same composition as the said gas mixture in the syringe.

12. The sterile pack of claim 11 , wherein the gaseous nitrogen is present in an amount ranging from 0.01% to 0.7% by volume.

13. The sterile pack of claim 11 , wherein the gaseous nitrogen is present in an amount ranging from 0.01% to 0.6% by volume.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2023
From: BTG INTERNATIONAL LIMITED
To: PROVENSIS LIMITED
Reel/Frame 065731/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2023
From: PROVENSIS LIMITED
To: BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED
Reel/Frame 065742/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2006
From: WRIGHT, DAVID DAKIN IORWERTH; HARMAN, ANTHONY DAVID; ROBINSON, NIKKI; HODGES, GARRY; KADAR, ADIL; MOGGRIDGE, GEOFFREY D; VAN LIEW, HUGH
To: BTG INTERNATIONAL LTD.
Reel/Frame 017583/0677 →